Centre Regional Lutte Contre Le Cancer — Clinical Trial Site

53 Registered trials

26 Currently recruiting

Organisation

Centre Regional Lutte Contre Le Cancer

Location

Strasbourg, France

Identifier

ORG-100054755

Address

Batiment Icans, 17 Rue Albert Calmette, 67200, France

Departments

#1004: Medical Oncology
#2101: Nuclear Medecine
#2155A; Oncologie
4005: Oncologie medicale
Gastro - entérologie
Gastroenterology
Médecine nucléaire
Medical oncolgy
Medical Oncology
N/A
Nuclear medicine
oncologie
Oncologie médicale
Oncology
radiotherapie
Radiotherapy
Service de pathologie mammaire
Service de radiothérapie
Service oncologie medicale

Clinical trials at this site (53)

Search interface

Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Pending

2025-521587-35-00 Metastatic colorectal cancer 5
Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending

2025-521619-37-00 Patients ≥75 years old with cT3/T4 rectal adenocarcinom 5
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Postmenopausal patients with small (pT1a-b pN0) hormone 4
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and… Recruiting

2025-522996-27-00 recurrent and/or metastatic squamous cell carcinoma of 5 2026-05-05
Visugromab in Cachexia International Trial Recruiting

2025-523533-25-00 Cancer-associated Cachexia 10 2026-03-26
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
IFCT-2401 SPORADIC a multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequ… Recruiting

2024-517316-29-00 Unresectable stage III Non-Small Cell Lung Cancer 4 2025-11-07
A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting

2024-519654-37-00 Recurrent or Metastatic Head and Neck Squamous Cell Car 10 2025-11-07
Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting

2025-520694-39-00 Metastatic or locally advanced irresectable (stage IV) 4 2025-10-24
Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un c… Recruiting

2025-522656-68-00 Metastatic breast cancers 6 2025-10-15
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub… Recruiting

2024-510893-25-00 Brain metastases of cancer > brain radionecrosis 5 2025-04-29
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Metastatic HER2-positive breast cancer 5 2024-12-03
Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent… Recruiting

2024-512297-96-01 Head and neck squamous cell carcinoma 4 2024-11-26
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) o… Recruiting

2023-509761-21-00 Metastatic colorectal cancer 5 2024-07-08
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting

2023-506590-35-00 Large-Cell NeuroEndocrine Carcinoma of the lung 4 2024-06-13
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
Treatment for breast cancer patients with meninges invaded by tumor cells Recruiting

2022-502351-60-00 Patients having a HER2-amplified metastatic breast canc 4 2024-02-22